Symbols / PMCB Stock $0.73 +1.14% PharmaCyte Biotech, Inc.

Healthcare • Biotechnology • United States • NCM
PMCB (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Joshua N. Silverman
Exch · Country NCM · United States
Market Cap 7.89M
Enterprise Value -11.86M
Income -7.49M
Sales —
FCF (ttm) -1.69M
Book/sh 3.59
Cash/sh 1.91
Employees 2
Insider 10d —
IPO Jan 02, 2013
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -1.93
PEG —
P/S —
P/B 0.20
P/C —
EV/EBITDA —
EV/Sales —
Quick Ratio 12.24
Current Ratio 12.33
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -0.89
EPS next Y -0.38
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2022-09-14
Earnings (prior) 2022-09-14
ROA -6.75%
ROE -8.24%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 10.74M
Shs Float 9.96M
Insider Own 5.74%
Instit Own 9.01%
Short Float 4.63%
Short Ratio 1.88
Short Interest 469.90K
52W High 1.51
vs 52W High -51.33%
52W Low 0.63
vs 52W Low 16.65%
Beta 0.46
Impl. Vol. 3.88%
Rel Volume 0.17
Avg Volume 199.31K
Volume 33.83K
Target (mean) —
Tgt Median —
Tgt Low —
Tgt High —
# Analysts —
Recom None
Prev Close $0.73
Price $0.73
Change 1.14%
About

PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company's cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. It also develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; license agreements with SG Austria Pte. Ltd.; and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$0.75
Latest analyst target
3. DCF / Fair value
$-2.84
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.75
Low
—
High
—
Mean
—

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2021-11-08 init HC Wainwright & Co. — → Neutral —
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-01-07 SCHECHTER JONATHAN L Director — 60,000 $0.78 $48,232
2025-12-12 WEINSTEIN ROBERT Director — 75,000 $0.00 $0
2025-12-12 WALKER WAYNE REMELL Director — 37,500 $0.00 $0
2025-12-12 SCHECHTER JONATHAN L Director — 150,000 $0.00 $0
2025-12-12 ABECASSIS MICHAEL M. M.D. Director — 37,500 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-04-30 2024-04-30 2023-04-30 2022-04-30
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
4.38
-32.85%
6.52
+1.00%
6.46
+46.98%
4.39
Research And Development
0.44
+7.60%
0.41
-13.04%
0.47
-32.19%
0.69
Selling General And Administration
3.94
-35.55%
6.11
+28.63%
4.75
+120.37%
2.16
General And Administrative Expense
3.94
-35.55%
6.11
+28.63%
4.75
+120.37%
2.16
Salaries And Wages
—
1.14
+19.96%
0.95
+270.91%
0.26
Other Gand A
3.94
-35.55%
6.11
+60.83%
3.80
+100.05%
1.90
Other Operating Expenses
—
1.32
+7.08%
1.23
-20.05%
1.54
Total Expenses
4.38
-32.85%
6.52
+1.00%
6.46
+46.98%
4.39
Operating Income
-4.38
+32.85%
-6.52
-1.00%
-6.46
-46.98%
-4.39
Total Operating Income As Reported
-4.38
+48.62%
-8.52
-31.98%
-6.46
-46.98%
-4.39
EBITDA
-4.38
+32.85%
-6.52
-1.00%
-6.46
-52.30%
-4.24
Normalized EBITDA
-38.00
-288.37%
-9.78
-51.56%
-6.46
-52.30%
-4.24
EBIT
-4.38
+32.85%
-6.52
-1.00%
-6.46
-52.30%
-4.24
Total Unusual Items
33.62
+930.06%
3.26
0.00
0.00
Total Unusual Items Excluding Goodwill
33.62
+930.06%
3.26
0.00
0.00
Special Income Charges
-2.02
+43.48%
-3.57
0.00
0.00
Other Special Charges
2.02
—
—
—
Impairment Of Capital Assets
0.00
-100.00%
2.00
0.00
—
Write Off
—
1.57
0.00
—
Net Income
30.66
+9084.98%
0.33
+107.73%
-4.32
-1.81%
-4.24
Pretax Income
30.66
+9084.98%
0.33
+107.73%
-4.32
-1.81%
-4.24
Net Non Operating Interest Income Expense
1.42
-58.35%
3.40
+75.42%
1.94
+1133.01%
0.16
Interest Expense Non Operating
—
—
0.00
-100.00%
0.00
Net Interest Income
1.42
-58.35%
3.40
+75.42%
1.94
+1133.01%
0.16
Interest Expense
—
—
0.00
-100.00%
0.00
Interest Income Non Operating
1.42
-58.35%
3.40
+75.42%
1.94
+1129.03%
0.16
Interest Income
1.42
-58.35%
3.40
+75.42%
1.94
+1129.03%
0.16
Other Income Expense
33.62
+873.05%
3.45
+1610.36%
0.20
+4816.37%
-0.00
Other Non Operating Income Expenses
-0.00
-100.50%
0.19
-5.37%
0.20
+4816.37%
-0.00
Gain On Sale Of Security
35.64
+421.33%
6.84
—
—
Tax Rate For Calcs
0.00
+0.00%
0.00
0.00
0.00
Tax Effect Of Unusual Items
7.06
+930.06%
0.69
0.00
0.00
Net Income Including Noncontrolling Interests
30.66
+9084.98%
0.33
+107.73%
-4.32
-1.81%
-4.24
Net Income From Continuing Operation Net Minority Interest
30.66
+9084.98%
0.33
+107.73%
-4.32
-1.81%
-4.24
Net Income From Continuing And Discontinued Operation
30.66
+9084.98%
0.33
+107.73%
-4.32
-1.81%
-4.24
Net Income Continuous Operations
30.66
+9084.98%
0.33
+107.73%
-4.32
-1.81%
-4.24
Normalized Income
4.10
+282.51%
-2.24
+47.99%
-4.32
-1.81%
-4.24
Net Income Common Stockholders
23.36
+235.53%
-17.24
-299.38%
-4.32
-1.81%
-4.24
Otherunder Preferred Stock Dividend
6.16
-59.05%
15.05
0.00
—
Diluted EPS
3.19
+277.22%
-1.80
-718.18%
-0.22
+18.52%
-0.27
Basic EPS
3.19
+277.22%
-1.80
-718.18%
-0.22
+18.52%
-0.27
Basic Average Shares
7.33
-23.50%
9.58
-50.84%
19.49
+25.56%
15.52
Diluted Average Shares
7.33
-23.50%
9.58
-50.84%
19.49
+25.56%
15.52
Diluted NI Availto Com Stockholders
23.36
+235.53%
-17.24
-299.38%
-4.32
-1.81%
-4.24
Gain On Sale Of PPE
0.00
+100.00%
-1.57
0.00
—
Preferred Stock Dividends
1.13
-55.13%
2.52
—
—
Line Item Trend 2025-04-30 2024-04-30 2023-04-30
Total Assets
55.17
-7.91%
59.90
-18.25%
73.28
Current Assets
22.38
-55.64%
50.44
-25.98%
68.15
Cash Cash Equivalents And Short Term Investments
15.54
-69.03%
50.18
-26.25%
68.04
Cash And Cash Equivalents
15.17
-69.76%
50.18
-26.25%
68.04
Other Short Term Investments
0.37
0.00
—
Receivables
3.70
0.00
—
Prepaid Assets
—
—
0.11
Hedging Assets Current
2.92
0.00
—
Other Current Assets
0.22
-13.87%
0.26
+141.27%
0.11
Total Non Current Assets
32.79
+246.50%
9.46
+84.51%
5.13
Goodwill And Other Intangible Assets
1.55
+0.00%
1.55
-56.35%
3.55
Other Intangible Assets
1.55
+0.00%
1.55
-56.35%
3.55
Investments And Advances
22.47
0.00
-100.00%
1.57
Other Non Current Assets
0.01
+0.00%
0.01
+0.00%
0.01
Total Liabilities Net Minority Interest
3.28
-83.93%
20.39
+3375.95%
0.59
Current Liabilities
2.91
-60.73%
7.42
+1165.17%
0.59
Payables And Accrued Expenses
2.91
+159.15%
1.12
+91.72%
0.59
Payables
0.42
-41.79%
0.73
+291.38%
0.19
Accounts Payable
0.40
+2.53%
0.39
+203.53%
0.13
Current Accrued Expenses
2.49
+530.09%
0.40
-1.27%
0.40
Total Tax Payable
0.03
-92.52%
0.34
+485.36%
0.06
Other Current Liabilities
—
6.30
—
Total Non Current Liabilities Net Minority Interest
0.36
-97.20%
12.97
0.00
Stockholders Equity
51.89
+31.32%
39.51
-45.64%
72.69
Common Stock Equity
51.89
+87.69%
27.65
-61.97%
72.69
Capital Stock
0.00
-99.98%
11.87
+549399.21%
0.00
Common Stock
0.00
+0.00%
0.00
+0.32%
0.00
Preferred Stock
0.00
-100.00%
11.87
0.00
Share Issued
21.67
+0.00%
21.67
+0.32%
21.60
Ordinary Shares Number
6.80
-15.45%
8.04
-52.14%
16.79
Treasury Shares Number
14.88
+9.11%
13.63
+183.57%
4.81
Additional Paid In Capital
181.49
-2.07%
185.33
-8.36%
202.23
Retained Earnings
-84.97
+26.51%
-115.63
+0.29%
-115.96
Gains Losses Not Affecting Retained Earnings
-0.02
-1.52%
-0.02
-2.21%
-0.02
Treasury Stock
44.61
+6.11%
42.04
+210.02%
13.56
Other Equity Adjustments
-0.02
-1.52%
-0.02
-2.21%
-0.02
Total Equity Gross Minority Interest
51.89
+31.32%
39.51
-45.64%
72.69
Total Capitalization
51.89
+31.32%
39.51
-45.64%
72.69
Working Capital
19.46
-54.76%
43.02
-36.33%
67.56
Invested Capital
51.89
+87.69%
27.65
-61.97%
72.69
Net Tangible Assets
50.34
+32.60%
37.97
-45.09%
69.14
Tangible Book Value
50.34
+92.89%
26.10
-62.25%
69.14
Derivative Product Liabilities
0.34
-97.39%
12.97
0.00
Financial Assets
8.76
+70.07%
5.15
0.00
Non Current Accrued Expenses
0.03
0.00
—
Non Current Note Receivables
0.00
-100.00%
2.75
0.00
Notes Receivable
3.70
0.00
—
Preferred Stock Equity
—
11.87
—
Line Item Trend 2025-04-30 2024-04-30 2023-04-30 2022-04-30
Operating Cash Flow
-2.98
-38.43%
-2.15
+43.29%
-3.79
+7.86%
-4.12
Cash Flow From Continuing Operating Activities
-2.98
-38.43%
-2.15
+43.29%
-3.79
+7.86%
-4.12
Net Income From Continuing Operations
30.66
+9084.98%
0.33
+107.73%
-4.32
-1.81%
-4.24
Other Non Cash Items
-21.23
-10785.50%
-0.20
-212.05%
0.17
+399.40%
0.03
Stock Based Compensation
0.48
-29.06%
0.67
+4.54%
0.65
+727.91%
0.08
Asset Impairment Charge
0.00
-100.00%
2.00
0.00
—
Operating Gains Losses
-8.17
-95.73%
-4.17
—
—
Gain Loss On Investment Securities
-8.17
-42.18%
-5.75
—
—
Unrealized Gain Loss On Investment Securities
-6.07
-457.51%
-1.09
0.00
—
Change In Working Capital
1.36
+353.78%
0.30
+200.58%
-0.30
-3387.23%
0.01
Change In Prepaid Assets
0.04
+123.69%
-0.15
-1026.06%
-0.01
+35.80%
-0.02
Change In Payables And Accrued Expense
1.32
+192.74%
0.45
+259.00%
-0.28
-1033.17%
0.03
Change In Accrued Expense
1.31
+589.99%
0.19
+566.54%
-0.04
-1406.07%
-0.00
Change In Payable
0.01
-96.23%
0.26
+207.47%
-0.24
-833.98%
0.03
Change In Account Payable
0.01
-96.23%
0.26
+207.47%
-0.24
-833.98%
0.03
Change In Other Current Assets
—
—
0.00
+100.00%
-0.00
Investing Cash Flow
-7.00
-40.00%
-5.00
0.00
0.00
Cash Flow From Continuing Investing Activities
-7.00
-40.00%
-5.00
0.00
—
Net Investment Purchase And Sale
-7.00
0.00
0.00
—
Purchase Of Investment
-7.00
0.00
—
—
Net Other Investing Changes
—
-5.00
—
—
Financing Cash Flow
-25.03
-133.74%
-10.71
+21.03%
-13.56
-115.53%
87.31
Cash Flow From Continuing Financing Activities
-25.03
-133.74%
-10.71
+21.03%
-13.56
-115.53%
87.31
Net Issuance Payments Of Debt
—
—
0.00
+100.00%
-0.05
Repayment Of Debt
—
—
0.00
+100.00%
-0.05
Long Term Debt Payments
—
—
0.00
+100.00%
-0.05
Net Long Term Debt Issuance
—
—
0.00
+100.00%
-0.05
Net Common Stock Issuance
-2.54
+90.98%
-28.20
-107.94%
-13.56
-115.52%
87.36
Common Stock Payments
-2.54
+90.98%
-28.20
-107.94%
-13.56
0.00
Repurchase Of Capital Stock
-25.03
+43.57%
-44.36
-227.11%
-13.56
0.00
Proceeds From Stock Option Exercised
0.00
-100.00%
0.00
-92.05%
0.00
0.00
Changes In Cash
-35.01
-96.02%
-17.86
-2.92%
-17.35
-120.86%
83.19
Effect Of Exchange Rate Changes
-0.00
+29.53%
-0.00
+92.99%
-0.01
-256.67%
0.00
Beginning Cash Position
50.18
-26.25%
68.04
-20.33%
85.40
+3778.14%
2.20
End Cash Position
15.17
-69.76%
50.18
-26.25%
68.04
-20.33%
85.40
Free Cash Flow
-2.98
-38.43%
-2.15
+43.29%
-3.79
+7.86%
-4.12
Interest Paid Supplemental Data
—
—
0.00
-100.00%
0.00
Income Tax Paid Supplemental Data
0.00
-100.00%
0.00
0.00
-100.00%
0.00
Common Stock Issuance
—
—
0.00
-100.00%
87.36
Issuance Of Capital Stock
0.00
-100.00%
33.65
0.00
-100.00%
87.36
Net Preferred Stock Issuance
-22.49
-228.57%
17.49
0.00
—
Preferred Stock Issuance
0.00
-100.00%
33.65
0.00
—
Preferred Stock Payments
-22.49
-39.15%
-16.16
0.00
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category